<DOC>
	<DOCNO>NCT00243932</DOCNO>
	<brief_summary>The purpose study determine efficacy prefer dose CoQ10 individual ALS possible future phase III study .</brief_summary>
	<brief_title>Clinical Trial High Dose CoQ10 ALS</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) progressive devastate neurodegenerative disorder . Available treatment ALS remain scarce . Oxidative stress mitochondrial dysfunction implicate pathophysiology ALS . Oxidative stress refers effect cell-damaging reactive oxygen specie , also know free radical . Oxidative stress think contribute nerve cell loss ALS . Mitochondria organelles within cell sometimes call `` powerhouse cell '' cellular energy metabolism locate within mitochondrion . Coenzyme Q10 ( CoQ10 ) , mitochondrial cofactor know antioxidant property , prolong survival mouse model ALS slow functional decline another neurodegenerative disorder , Parkinson 's disease . The goal double-blind , placebo-controlled , two-dose comparison phase II study obtain preliminary efficacy data select prefer dose large phase III study . Participants randomly assign CoQ10 ( two different dose level ) placebo first stage , 2,700 mg dose select second stage . Duration trial 9 month total 7 visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Clinical diagnosis definite , probable , laboratorysupported probable ALS Negative pregnancy test woman childbearing age adequate birth control measure Subjects must able willing give inform consent must capable comply trial procedure Forced Vital Capacity ( FVC ) &gt; /= 60 % predict Age 21 85 year , inclusive Disease duration le 5 year Subjects may take riluzole ( without change dose 30 day enrollment ) Patients take CoQ10 past eligible stop least 30 day enrollment Patients take vitamin E past eligible stop least 14 day enrollment Dependency mechanical ventilation ( noninvasive ventilation &gt; 23 hour ) Severe unstable concomitant medical psychiatric illness Insufficiently control diabetes mellitus Concomitant warfarin therapy Women breast feed high likelihood pregnancy Significant hepatic dysfunction Forced Vital Capacity ( FVC ) less 60 % Exposure CoQ10 within 30 day enrollment Exposure experimental medication within 30 day enrollment Exposure vitamin E within 14 day enrollment Sensitivity color additive FD &amp; C Yellow No . 5 Sensitivity aspirin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>CoQ10</keyword>
	<keyword>coenzyme Q10</keyword>
	<keyword>antioxidant</keyword>
	<keyword>free radical</keyword>
	<keyword>mitochondrial dysfunction</keyword>
</DOC>